STK11 and non-small cell lung carcinoma: Therefore, the prognosis of patients with LKB1 mutated NSCLC has been the focus of substantial attention; and related therapeutic clinical trials, requiring LKB1 mutation as a determinant or investigation inclusion criteria, have been conducted.